Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Agile Therapeutics's share price for the quarter that ended in Mar. 2024 was $0.34. Agile Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 6.86 Mil. Therefore, Agile Therapeutics's market cap for the quarter that ended in Mar. 2024 was $2.33 Mil.
Agile Therapeutics's quarterly market cap
increased
from Sep. 2023 ($5.47 Mil) to Dec. 2023 ($5.78 Mil) but then
declined
from Dec. 2023 ($5.78 Mil) to Mar. 2024 ($2.33 Mil).
Agile Therapeutics's annual market cap
declined
from Dec. 2021 ($59.26 Mil) to Dec. 2022 ($9.75 Mil) and
declined
from Dec. 2022 ($9.75 Mil) to Dec. 2023 ($5.78 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Agile Therapeutics's Enterprise Value for Today is $0.25 Mil.
Agile Therapeutics Market Cap Historical Data
The historical data trend for Agile Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Agile Therapeutics's Market Cap
For the Drug Manufacturers - Specialty & Generic subindustry, Agile Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agile Therapeutics's Market Cap Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Agile Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Agile Therapeutics's Market Cap falls into.
Agile Therapeutics Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Agile Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agile Therapeutics (OTCPK:AGRX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Agile Therapeutics Market Cap Related Terms
Thank you for viewing the detailed overview of Agile Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Agile Therapeutics (Agile Therapeutics) Business Description
Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Its product candidates are designed to provide women with contraceptive options. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. The Company views its operations and manages its business in one operating and reporting segment, which is the business of commercializing its transdermal patch for use in contraception.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AGRX has been successfully added to your 